

Declaration of Interests Register

Technology Appraisal Committee A


Topic: Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer [TA632]

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments
				Interest arose	Interest declared	Interest ceased	
Professor Andrew Wardley	Clinical Expert	Financial interest	Consultancy and speaker fees from Roche, advising and talking on treatment in breast cancer including those directly related to this appraisal.	24/03/2020	24/03/2020	-	Declaration made and participated in the appraisal Agreed by Chair Dr Jane Adam
Professor Mark Verrill	Clinical Expert	Financial interest	Received fees from Roche for advisory boards, consultancy and lecturing,	24/03/2020	24/03/2020	-	Declaration made and participated in the appraisal Agreed by Chair Dr Jane Adam

Link to Committee A interests register : https://www.nice.org.uk/Media/Default/Get-involved/Meetings-In-Public/Technology-appraisal-committee/TAC-A-interests-register.pdf

GUIDANCE NOTES FOR COMPLETION OF THE INTERESTS REGISTER

Publication Date: 10/06/2020



Relevant dates: Detail here the date the interest arose, the date it was first declared and when it ceased, if applicable. For example, if an individual has

ceased to hold shares or undertake relevant private practice.